The Study of Clinical Outcomes, Cartilage Biomarkers and Hemophilic Arthropathy (HEAD-US) in Hemophilia A Patients : Low Dose Emicizumab vs. Pharmacokinetic-Guided Extended Half-Life FVIII Concentrates
Latest Information Update: 04 Mar 2026
At a glance
- Drugs Emicizumab (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
Most Recent Events
- 04 Mar 2026 New trial record